Journalism of Courage
Advertisement
Rahul Rao
Follow
Rahul Rao is an Equity Analyst. He bought his first stock in 2014 and has been active in the Indian stock market ever since. In his first job, he helped conduct one of the largest financial literacy sessions in the country between 2015 – 2021 for more than 1,50,000 investors. He helped start a family office for a 50-year-old conglomerate and worked at an AIF, focusing on small and mid-cap opportunities. He evaluates stocks using an evidence-based, first-principles approach as opposed to comforting narratives. Rahul is a CFA Charter holder. He also has a Bachelor’s degree in Aerospace Engineering.
More From Rahul Rao
Concord Biotech: A bad year or a bigger opportunity?Subscriber Only
July 22, 2026 07:30 IST
Concord Biotech had its toughest year as a listed company, with revenue and profit falling sharply. But a closer look reveals a business with strong positions in niche fermentation-based APIs, significant spare capacity and potential operating leverage. The question is whether FY26 was a temporary setback, or the start of a structural slowdown.
Tue, Jul 21, 2026
PCBL Chemicals: Can its diversification drive the next growth cycle?Subscriber Only
July 11, 2026 07:30 IST
India's largest carbon black producer is transforming into a specialty chemicals company through phosphonates, specialty black, and battery materials. But after a weak FY26, can these bets reignite earnings?
Sat, Jul 11, 2026
AAA rating, 0.55% ROA: What Emirates NBD really bought in RBL BankSubscriber Only
July 07, 2026 06:30 IST
RBL Bank has a new owner, an AAA credit rating and Rs 26,016 crore in fresh capital. Yet its return on assets remains just 0.55%. As Emirates NBD bets on the lender's future, the bigger question is whether a stronger balance sheet can translate into stronger earnings.
Tue, Jul 07, 2026
Aarti Pharmalabs: Can its CDMO bet revive growth after a weak year?Subscriber Only
July 02, 2026 06:42 IST
A caffeine giant, a growing CDMO business, and a recovering API segment. Can Aarti Pharmalabs convert a Rs 1,300+ crore capex cycle into a compounding pharma platform?
Thu, Jul 02, 2026
Centum Electronics: Why a Rs 52-crore loss hasn’t derailed the rallySubscriber Only
June 26, 2026 06:30 IST
Reported a Rs 52-crore FY26 loss and a negative P/E, yet Centum Electronics trades near record highs. A one-time cleanup has revealed a faster-growing India business. The question now: does 50x earnings still make sense?
Thu, Jun 25, 2026
Syngene International: Could India’s WuXi moment finally be here?Subscriber Only
June 23, 2026 06:30 IST
A difficult FY26, years of capability building, and the Pentagon's designation of WuXi AppTec may be converging to create the biggest opportunity in Syngene's history.
Mon, Jun 22, 2026
WPIL’s Rs 6,000-cr order book is growing. Why isn’t the market convinced?Subscriber Only
June 17, 2026 07:30 IST
WPIL's stock has halved as its domestic business stumbled, but strong international operations have cushioned the blow. With a record order book and a valuation of just 2.7 times book value, can fresh project wins and improved cash generation drive the next leg of growth?
Wed, Jun 17, 2026
Honasa Consumer is growing again, but can it keep margins intact?Subscriber Only
June 16, 2026 06:30 IST
EBITDA tripled, PAT jumped 2.7x, and Honasa declared its first dividend. But margins expanded because advertising costs fell, not because the business became structurally more profitable. At 66x earnings, is the turnaround real, or has the market already priced it in?
Mon, Jun 15, 2026
After a 38% rally, can VA Tech Wabag deliver more?Subscriber Only
June 12, 2026 06:30 IST
The business transformed first. The stock followed later. After years of being overlooked, VA Tech Wabag has been re-rated sharply. The question now is whether its growth, cash generation and order pipeline justify 27x earnings.
Tue, Jun 16, 2026
Can Supriya Life Sciences unlock its next leg of growth beyond APIs?Subscriber Only
June 06, 2026 06:30 IST
Over the last few years, Supriya Life Sciences has expanded beyond its traditional API business. By targeting markets dominated by Chinese suppliers and investing in formulations, contrast media APIs, peptides, and CDMO services, the company is increasing its presence across the pharmaceutical value chain. The key question is whether these initiatives can transform it into a diversified pharmaceutical player.
Fri, Jun 05, 2026
Gujarat Themis Biosyn’s Rs 3,000 crore bet: Can it build a global pharma platform?Subscriber Only
June 03, 2026 06:30 IST
A small-cap API intermediate manufacturer is attempting a transformation into a global pharmaceutical platform through Rs 3,000 crore of acquisitions, including Sanofi's anti-TB brands and Japan's MicroBiopharm. The opportunity is compelling, but can the balance sheet support the ambition?
Wed, Jun 03, 2026
From scooter frames to satellite parts: Belrise’s quiet push into the global aerospace supply chainSubscriber Only
May 30, 2026 06:30 IST
A 2W-metal company is quietly buying its way into aerospace and satellite supply chains. It saw its FY26 profit after tax jump 41%, reduced its net debt to near zero, and watched its stock double. At ~40x, is the aerospace bet already in the price?
Fri, May 29, 2026
Specialty chemicals, peptides, and pricing recovery: The Alkyl Amines opportunitySubscriber Only
May 27, 2026 07:30 IST
Alkyl Amines Chemicals manufactures critical reagents used in peptide synthesis and pharmaceutical chemistry. With global leadership in several amine molecules and exposure to the GLP-1 ecosystem, the company is emerging as a key beneficiary of India’s pharmaceutical manufacturing scale-up. The question now is whether execution can keep pace with the scale of the opportunity.
Wed, May 27, 2026
Manorama Industries: Can growth sustain the valuation?Subscriber Only
May 21, 2026 06:30 IST
Manorama Industries’ FY26 revenue grew 76%, ROE touched 40%, and EBITDA margin expanded to 27%. The stock now trades at 34x earnings. But after two years of negative operating cash flow before a sharp rebound in FY26, the key question is whether margins, capacity expansion, pricing power, and cash conversion can continue to hold together.
Wed, May 20, 2026
Acutaas Chemicals: The specialty chemicals story the market is re-rating fastSubscriber Only
May 18, 2026 06:30 IST
Acutaas Chemicals was once viewed primarily as a pharmaceutical intermediates manufacturer. Today, the company is building a broader specialty chemicals platform spanning CDMO, battery electrolyte additives, semiconductor chemicals, and fine chemistry. As multiple growth engines begin scaling simultaneously, the key question is whether execution can justify the sharp valuation re-rating already underway.
Sun, May 17, 2026
45% EPS CAGR, 29% ROE: What’s driving Solar Industries’ growth?Subscriber Only
May 16, 2026 06:30 IST
A Rs 21,200 crore order book, the commercial rollout of Pinaka rockets, and rapidly scaling international defence orders are transforming Solar Industries from an industrial explosives maker into one of India’s fastest-growing defence manufacturers. Investors are now watching whether this momentum can sustain the company’s next phase of compounding.
Sat, May 16, 2026
OneSource Specialty Pharma: A capacity-led bet on the GLP-1 gold rushSubscriber Only
May 09, 2026 07:30 IST
OneSource Specialty Pharma is emerging as a surprising beneficiary of the global GLP-1 boom. With semaglutide patents set to expire across key markets and demand for injection pens surging, the Bengaluru-based CDMO is scaling aggressively for what could become a multi-year manufacturing opportunity.
Fri, May 08, 2026
Inside Adani Green’s high-leverage bet on India’s 500 GW energy transitionSubscriber Only
May 08, 2026 07:30 IST
Adani Green Energy added more renewable capacity in FY26 than any company outside China, accounting for nearly 9% of India’s total clean energy additions. But behind the record growth lies transmission bottlenecks, Rs 1,500 crore of voluntarily sacrificed EBITDA, rising debt, and an aggressive battery storage push that could define the next phase of India’s energy transition.
Thu, May 07, 2026
After a 4x rally and 92.5% EBITDA surge, what lies ahead for MTAR Technologies?Subscriber Only
May 02, 2026 06:30 IST
For years, MTAR Technologies operated under the radar, building components across nuclear, clean energy, and defence. Now, as global demand converges across these sectors, its order book is surging and capacity is stretched. With deep technical moats and multiple growth engines firing at once, the question now is: are the valuations stretched?
Sat, May 02, 2026
CP PLUS hits 39% market share, but can it hold on?Subscriber Only
April 29, 2026 06:30 IST
In Q3 FY26, CP Plus's revenue grew 37% year-on-year, while adjusted PAT surged 139% and EBITDA margins expanded from 8.3% in FY25 to 12.7%. In a weak broader market, such momentum raises two questions: what is driving this transformation, and do current valuations still hold up?
Tue, Apr 28, 2026
Natco Pharma: A high-margin business or a volatility trap at 10x earnings?Subscriber Only
April 22, 2026 06:30 IST
Despite 30%+ margins and exposure to the GLP-1 opportunity, Natco Pharma continues to trade at a modest valuation. Is the 10x P/E a structural constraint or a mispriced opportunity?
Wed, Apr 22, 2026
53 million tonnes output, 33% margins, 10x earnings: NMDC’s volume-price paradoxSubscriber Only
April 15, 2026 06:30 IST
NMDC just delivered its best year ever, crossing 50 million tonnes of iron ore production. But falling prices, rising costs, and Rs 10,000+ crore stuck in receivables are keeping profits, and the stock, under pressure.
Tue, Apr 14, 2026
From losses to 27% EBITDA: Decoding GE Vernova’s transformation storySubscriber Only
April 10, 2026 06:30 IST
A company that was loss-making in FY22 now trades at 85x earnings. The question for investors is whether GE Vernova’s margin expansion and order pipeline justify the premium, or if expectations have run ahead of reality.
Thu, Apr 09, 2026
From lab project to market leader: Can Ather Energy justify a 9x revenue multiple?Subscriber Only
April 04, 2026 06:30 IST
A decade after it began as a robotics lab experiment at IIT Madras, Ather Energy has emerged as one of India’s leading electric two-wheeler makers, with an 18% market share. Revenues are rising, margins are expanding, and losses are narrowing. But with the stock trading at a 9x P/S and competition intensifying, the key question is whether this momentum reflects a durable structural shift or a favourable cycle.
Fri, Apr 03, 2026
NTPC’s Rs 7 lakh crore bet: Coal, clean energy and compounding returnsSubscriber Only
March 31, 2026 06:30 IST
Even as global sentiment turns against coal, NTPC is doubling down on thermal capacity while expanding into renewables, nuclear, and storage, and relying on a regulated framework that ensures stable returns. The question now is whether NTPC can accelerate earnings growth beyond its steady compounding base.
Tue, Mar 31, 2026
Install IE App for better experience
Featured
Trending Topics
News
Multimedia
Follow Us